Scpharmaceuticals’ (SCPH) “Buy” Rating Reiterated at Jefferies Group

Jefferies Group reiterated their buy rating on shares of Scpharmaceuticals (NASDAQ:SCPH) in a research note released on Wednesday. They currently have a $26.00 price objective on the stock. Jefferies Group also issued estimates for Scpharmaceuticals’ FY2019 earnings at ($2.36) EPS, FY2020 earnings at ($1.53) EPS, FY2021 earnings at $0.47 EPS and FY2022 earnings at $2.01 EPS.

Several other research firms have also issued reports on SCPH. Leerink Swann assumed coverage on shares of Scpharmaceuticals in a research note on Tuesday, December 12th. They issued an outperform rating and a $20.00 target price for the company. BMO Capital Markets assumed coverage on shares of Scpharmaceuticals in a research note on Tuesday, December 12th. They issued an outperform rating and a $24.00 target price for the company. Finally, Zacks Investment Research lowered shares of Scpharmaceuticals from a hold rating to a sell rating in a research note on Wednesday, February 14th.

How to Become a New Pot Stock Millionaire

Shares of SCPH stock opened at $12.42 on Wednesday. Scpharmaceuticals has a one year low of $11.50 and a one year high of $18.17.

Scpharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Tuesday, March 20th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.27). equities research analysts expect that Scpharmaceuticals will post -2.75 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. AWM Investment Company Inc. bought a new stake in shares of Scpharmaceuticals in the 4th quarter worth $1,996,000. Nicholas Investment Partners LP bought a new position in Scpharmaceuticals during the fourth quarter valued at about $1,500,000. Bain Capital Public Equity Management LLC bought a new position in Scpharmaceuticals during the fourth quarter valued at about $1,291,000. Goldman Sachs Group Inc. bought a new position in Scpharmaceuticals during the fourth quarter valued at about $653,000. Finally, Millennium Management LLC bought a new position in Scpharmaceuticals during the fourth quarter valued at about $462,000. Hedge funds and other institutional investors own 44.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Scpharmaceuticals’ (SCPH) “Buy” Rating Reiterated at Jefferies Group” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3298596/scpharmaceuticals-scph-buy-rating-reiterated-at-jefferies-group.html.

Scpharmaceuticals Company Profile

scPharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in developing pharmaceutical products for subcutaneous delivery. The Company offers sc2Wear Infusor, which is a small pump that attaches to the body using a standard medical adhesive. The sc2Wear Infusor injects the drug into the body slowly, similar to an intravenous (IV) drip.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Robert Half International  Trading 0.3% Higher  on Analyst Upgrade
Robert Half International Trading 0.3% Higher on Analyst Upgrade
Texas Instruments  Shares Gap Up  on Analyst Upgrade
Texas Instruments Shares Gap Up on Analyst Upgrade
Samuel Adams  Hits New 1-Year High and Low After Strong Earnings
Samuel Adams Hits New 1-Year High and Low After Strong Earnings
Peoples Financial Services  Announces  Earnings Results
Peoples Financial Services Announces Earnings Results
Tupperware Brands  Issues Q2 Earnings Guidance
Tupperware Brands Issues Q2 Earnings Guidance
SEACOR  Posts  Earnings Results, Beats Expectations By $0.04 EPS
SEACOR Posts Earnings Results, Beats Expectations By $0.04 EPS


© 2006-2018 Ticker Report. Google+.